Parkinson’s UK is pleased to announce a new project worth £1.2million to fund essential research towards new treatment that could both improve symptoms and slow the progression of Parkinson’s.

New international research suggests that too much calcium inside brain cells may trigger a chain reaction that leads to Parkinson's.

We're partnering with US company Neurolixis to accelerate the development of a drug that could prevent dyskinesia, a debilitating side effect of Parkinson's medication.

A study, featured in the Daily Mail, suggests a link between certain types of flu and risk of Parkinson's.

International pharmaceutical company, Pfizer, has announced a move to end all early-stage projects in neuroscience.

New figures from Parkinson's UK show that more than 12,000 Scots are now living with Parkinson's, and numbers are continuing to rise.

The number of people diagnosed and living with Parkinson’s is increasing, according to our latest research.

Researchers in Japan have discovered that people with Parkinson's may have lower levels of caffeine in their blood after drinking tea and coffee.

New research demonstrates how the protein alpha-synuclein could cause the loss of cells in Parkinson’s.

Research supported by Parkinson's UK has identified a medicine used to treat tapeworm infections which could lead to new treatments for people with Parkinson's.